Menu

Jutta Wanner, Ph.D.

Advisor, Founding Scientist (OST-tADC)
Dr. Jutta Wanner, former CSO at BlinkBio, brings her Advanced ADC technology and expertise in oncology, inflammation, and virology. She previously co-led discovery chemistry at Roche and holds a PhD from the University of Kansas.
See full team
Jutta Wanner
Background

Dr. Jutta Wanner joins her Tunable Drug Conjugate (Advanced ADC) technology from BlinkBio, where she was Chief Scientific Officer. Before that she was at Roche where she was a co-lead in discovery chemistry. Dr. Wanner brings expertise across multiple therapeutic areas including oncology, inflammation and virology. Dr. Wanner received her PhD from the University of Kansas and conducted her postdoctoral training at The Scripps Research Institute in San Diego.

Our Pipeline

The Future of Cancer Treatment

OS Therapies is not just addressing Osteosarcoma. With the other uses of our HER2 target cancer immunotherapy and the addition of our OST-tADC tunable Antibody Drug Conjugate silicone linker platform, we are paving the way for the next-generation of cancer treatments.
Female chemist working on osteosarcoma treatments | OS TherapiesLab technician working on cancer treatments | OS TherapiesFemale chemist working on cancer treatments